Ultragenyx Pharmaceutical (RARE) Leases (2019 - 2023)

Ultragenyx Pharmaceutical (RARE) has 5 years of Leases data on file, last reported at $26.4 million in Q3 2023.

• Quarterly Leases fell 8.08% year-over-year to $26.4 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $26.4 million (down 8.08% YoY) and the FY2022 annual result came in at $26.0 million, down 25.69% from the prior year.
• Leases improved to $26.4 million in Q3 2023 per RARE's latest filing, from $19.2 million in the prior quarter.
• Across five years, Leases topped out at $40.5 million in Q4 2020 and bottomed at $19.2 million in Q2 2023.
• The 5-year median for Leases is $32.2 million (2019), against an average of $31.6 million.
• The widest annual swing landed in 2020, when Leases soared 55.61%; it then tumbled 38.48% in 2023.
• Tracing RARE's Leases over 5 years: stood at $30.3 million in 2019, then surged by 33.62% to $40.5 million in 2020, then dropped by 13.79% to $34.9 million in 2021, then decreased by 25.69% to $26.0 million in 2022, then grew by 1.8% to $26.4 million in 2023.
• Per Business Quant, the three latest RARE Leases figures stand at $26.4 million (Q3 2023), $19.2 million (Q2 2023), and $22.9 million (Q1 2023).

Peer Comparison